Difficult decisions in the cost-effectiveness analysis of new cancer treatments

The value of cancer treatment varies. In The Netherlands ENDO was formed to reach consensus on the value of treatment with a newly developed tool. Professors Willemse and Tjan-Heijnen, former chairs of this committee, together look at the intrinsic difficulties of valuing new cancer treatments.